SRXH Enters $2.86M Private Placement for Series C Preferred Stock via Note Exchange

SRX Global Inc. entered into a securities purchase agreement with accredited investors to issue 3,579 shares of its new Series C convertible preferred stock. The total purchase price of $2,862,500 was satisfied by the investors assigning convertible promissory notes from CERO Therapeutics Holdings, Inc. to SRX Global.

Key Details

• Agreement: On August 27, 2026, SRX Global agreed to sell 3,579 shares of Series C convertible preferred stock for a purchase price of $2.86 million.
• Payment Structure: The purchase was non-cash, satisfied by investors assigning convertible notes from CERO Therapeutics with an aggregate principal amount of $2.81 million to the company.
• Security Terms: Each share of Series C preferred stock has a stated value of $1,000 and is convertible into common stock at a fixed price of $2.1888 per share. The terms include alternative conversion options at a discount to the market price following stockholder approval or upon a triggering event.
• Registration Rights: The company entered into a registration rights agreement, obligating it to file a registration statement for the resale of the common stock issuable upon conversion of the Series C shares.